No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. The company's operations are divided into four main divisions: Proprietary Products, Distribution, Technical Services, and Other Business Ventures. Its advanced ophthalmic instruments are crucial for the diagnosis, treatment, and surgical intervention of a broad spectrum of eye conditions, including vitreoretinal disorders, cataracts, glaucoma, refractive errors, ocular surface diseases, and issues in optometry and pediatric ophthalmology. The Proprietary Products division focuses on creating and producing its own line of surgical apparatus, accompanying software, intraocular lenses, and equipment for diagnosing and treating eye ailments, along with their associated consumables. Conversely, the Distribution division is responsible for selling diagnostic devices, equipment for ocular fundus examination, surgical and treatment instruments, and related consumables. The Technical Services segment provides essential support, covering warranty services, maintenance, and the supply of post-sales consumables. Lastly, the Other Business Ventures division handles equipment rental, agent registration services, and the licensing of intellectual property. Gaush Meditech Ltd. reaches its clientele—comprising public and private hospitals, among other customers—through both direct sales and a network of distributors. The company was established in 1998 and has its corporate headquarters situated in Beijing, China.
www.gaush.comNo one on the platform currently holds 2407.HK.
No tracked institution reports a position in 2407.HK as of their last filing.
No one on the platform has traded 2407.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.6% | — | — | — | ||
| Rev. Growth % | -3.4% | 7.5% | ||||
| Profit Margin % | 7.0% | -3.4% | ||||
| Free Cash Flow Margin % | 8.0% | 9.9% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.0B | +15.1% | $1.43 | $1.43–$1.43 | — | 1 |
| 2027 | $2.2B | +9.3% | $1.69 | $1.69–$1.69 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2407.HKGaush Meditech Ltd | $4.65 | +0.00% | $688M | — |
| 0950.HKLee's Pharmaceutical Holdings Limited | $1.14 | -1.30% | $668M | — |
| 1526.HKRici Healthcare Holdings Limited | $0.81 | -4.71% | $1.3B | — |
| 1846.HKEuroEyes International Eye Clinic Limited | $2.30 | +0.00% | $735M | — |
| 2137.HKBrii Biosciences Limited | $0.85 | -2.86% | $613M | — |
| 2216.HKBroncus Holding Corporation | $0.62 | -2.36% |
Source: Financial Modeling Prep · peers by sector/industry
| $326M |
| — |
| 2219.HKChaoju Eye Care Holdings Limited | $2.44 | -1.42% | $1.7B | — |